Related references
Note: Only part of the references are listed.Interventions for older people having cancer treatment: A scoping review
Naomi Farrington et al.
JOURNAL OF GERIATRIC ONCOLOGY (2020)
Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology
Philipp Nuhn et al.
EUROPEAN UROLOGY (2019)
Updated recommendations of the International Society of Geriatric Oncology on prostate cancer management in older patients
H. J. Boyle et al.
EUROPEAN JOURNAL OF CANCER (2019)
Health-related Quality of Life for Abiraterone Plus Prednisone Versus Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer: Results from a Phase II Randomized Trial
Daniel J. Khalaf et al.
EUROPEAN UROLOGY (2019)
Metastatic Prostate Cancer
Oliver Sartor et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
A comparison of the CARG tool, the VES-13, and oncologist judgment in predicting grade 3+toxicities in men undergoing chemotherapy for metastatic prostate cancer
Shabbir M. H. Alibhai et al.
JOURNAL OF GERIATRIC ONCOLOGY (2017)
Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAIL
J. N. Graff et al.
ANNALS OF ONCOLOGY (2016)
A prospective study examining elder-relevant outcomes in older adults with prostate cancer undergoing treatment with chemotherapy or abiraterone
Tharsika Manokumar et al.
JOURNAL OF GERIATRIC ONCOLOGY (2016)
Treatment of mCRPC in the AR-axis-targeted therapy-resistant state
K. Chi et al.
ANNALS OF ONCOLOGY (2015)
Cancer Statistics, 2015
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2015)
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
Christopher J. Sweeney et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Efficacy and toxicity of abiraterone and docetaxel in octogenarians with metastatic castration-resistant prostate cancer
Raya Leibowitz-Amit et al.
JOURNAL OF GERIATRIC ONCOLOGY (2015)
Prediction of treatment-related toxicity and outcome with geriatric assessment in elderly patients with solid malignancies treated with chemotherapy: a systematic review
K. S. Versteeg et al.
ANNALS OF ONCOLOGY (2014)
The impact of low-grade toxicity in older people with cancer undergoing chemotherapy
T. Kalsi et al.
BRITISH JOURNAL OF CANCER (2014)
Supportive Care Considerations for Older Adults With Cancer
Arash Naeim et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Screening for Vulnerability in Older Cancer Patients: The ONCODAGE Prospective Multicenter Cohort Study
Pierre Soubeyran et al.
PLOS ONE (2014)
Tolerability and efficacy of docetaxel in older men with metastatic castrate-resistant prostate cancer (mCRPC) in the TAX 327 trial
Anne M. Horgan et al.
JOURNAL OF GERIATRIC ONCOLOGY (2014)
Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials
A. J. Templeton et al.
ANNALS OF ONCOLOGY (2013)
Analysis of docetaxel therapy in elderly (≥70 years) castration resistant prostate cancer patients enrolled in the Netherlands Prostate Study
F. L. Gerritse et al.
EUROPEAN JOURNAL OF CANCER (2013)
2-weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial
Pirkko-Liisa Kellokumpu-Lehtinen et al.
LANCET ONCOLOGY (2013)
Predicting the risk of chemotherapy toxicity in older patients: The Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score
Martine Extermann et al.
CANCER (2012)
Predicting Chemotherapy Toxicity in Older Adults With Cancer: A Prospective Multicenter Study
Arti Hurria et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Implementing a Geriatric Assessment in Cooperative Group Clinical Cancer Trials: CALGB 360401
Arti Hurria et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Docetaxel-Based Chemotherapy in Elderly Patients (Age 75 and Older) with Castration-Resistant Prostate Cancer
Antoine Italiano et al.
EUROPEAN UROLOGY (2009)
Perspectives, preferences, care practices, and outcomes among older and middle-aged patients with late-stage cancer
JH Rose et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
IF Tannock et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Are older French patients as willing as older American patients to undertake chemotherapy?
M Extermann et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
The vulnerable elders survey: A tool for identifying vulnerable older people in the community
D Saliba et al.
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY (2001)
Share Paper
